Neville Rodie & Shaw Inc. Has $2.51 Million Position in Intuitive Surgical, Inc. $ISRG

Neville Rodie & Shaw Inc. cut its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 30.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,320 shares of the medical equipment provider’s stock after selling 2,802 shares during the quarter. Neville Rodie & Shaw Inc.’s holdings in Intuitive Surgical were worth $2,513,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ISRG. Draper Asset Management LLC increased its position in shares of Intuitive Surgical by 41.9% in the fourth quarter. Draper Asset Management LLC now owns 5,029 shares of the medical equipment provider’s stock worth $2,848,000 after purchasing an additional 1,485 shares during the period. Deutsche Bank AG lifted its position in Intuitive Surgical by 9.6% during the fourth quarter. Deutsche Bank AG now owns 1,522,191 shares of the medical equipment provider’s stock worth $862,108,000 after purchasing an additional 132,966 shares during the period. Oppenheimer Asset Management Inc. grew its stake in Intuitive Surgical by 29.3% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 71,077 shares of the medical equipment provider’s stock worth $40,255,000 after buying an additional 16,119 shares in the last quarter. Robinhood Asset Management LLC acquired a new stake in Intuitive Surgical during the fourth quarter worth about $6,478,000. Finally, KBC Group NV increased its holdings in Intuitive Surgical by 4.7% in the 4th quarter. KBC Group NV now owns 420,593 shares of the medical equipment provider’s stock valued at $238,207,000 after buying an additional 18,697 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Iman Jeddi sold 5,625 shares of Intuitive Surgical stock in a transaction on Monday, June 1st. The shares were sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the transaction, the senior vice president owned 6,463 shares in the company, valued at approximately $2,718,014.65. The trade was a 46.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the business’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total transaction of $169,656.00. Following the completion of the sale, the executive vice president directly owned 5,720 shares in the company, valued at approximately $2,426,080.80. This represents a 6.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,634 shares of company stock worth $2,796,795 over the last three months. Insiders own 0.60% of the company’s stock.

Intuitive Surgical Stock Down 1.9%

Shares of ISRG opened at $368.27 on Wednesday. The stock has a market cap of $130.10 billion, a PE ratio of 42.18, a PEG ratio of 2.71 and a beta of 1.46. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88. The business has a 50-day simple moving average of $395.65 and a two-hundred day simple moving average of $448.56.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same period last year, the firm posted $1.81 earnings per share. The business’s revenue for the quarter was up 18.4% on a year-over-year basis. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Analysts Set New Price Targets

ISRG has been the subject of several analyst reports. Raymond James Financial restated an “outperform” rating and issued a $483.00 target price (down from $577.00) on shares of Intuitive Surgical in a research report on Friday, July 17th. TD Cowen lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating on the stock in a research note on Friday, July 17th. Evercore set a $430.00 target price on Intuitive Surgical in a research note on Monday, July 6th. Finally, Bank of America reduced their target price on Intuitive Surgical from $520.00 to $515.00 in a report on Friday, June 12th. Twenty investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $509.02.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.